BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 15269146)

  • 21. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients.
    Domínguez G; Carballido J; Silva J; Silva JM; García JM; Menéndez J; Provencio M; España P; Bonilla F
    Clin Cancer Res; 2002 Apr; 8(4):980-5. PubMed ID: 11948103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypermethylation of the 5'CpG island of the FHIT gene in clear cell renal carcinomas.
    Kvasha S; Gordiyuk V; Kondratov A; Ugryn D; Zgonnyk YM; Rynditch AV; Vozianov AF
    Cancer Lett; 2008 Jul; 265(2):250-7. PubMed ID: 18378390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma.
    Peng CY; Chen TC; Hung SP; Chen MF; Yeh CT; Tsai SL; Chu CM; Liaw YF
    Anticancer Res; 2002; 22(2B):1265-71. PubMed ID: 12168936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
    Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
    Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers.
    Sanchez-Cespedes M; Decker PA; Doffek KM; Esteller M; Westra WH; Alawi EA; Herman JG; Demeure MJ; Sidransky D; Ahrendt SA
    Cancer Res; 2001 Mar; 61(5):2092-6. PubMed ID: 11280771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alterations of p16(INK4a) and p14(ARF) in patients with severe oral epithelial dysplasia.
    Kresty LA; Mallery SR; Knobloch TJ; Song H; Lloyd M; Casto BC; Weghorst CM
    Cancer Res; 2002 Sep; 62(18):5295-300. PubMed ID: 12234999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene amplification is a relatively frequent event leading to ZBTB7A (Pokemon) overexpression in non-small cell lung cancer.
    Apostolopoulou K; Pateras IS; Evangelou K; Tsantoulis PK; Liontos M; Kittas C; Tiniakos DG; Kotsinas A; Cordon-Cardo C; Gorgoulis VG
    J Pathol; 2007 Nov; 213(3):294-302. PubMed ID: 17907153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
    Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
    Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer.
    Bearzatto A; Conte D; Frattini M; Zaffaroni N; Andriani F; Balestra D; Tavecchio L; Daidone MG; Sozzi G
    Clin Cancer Res; 2002 Dec; 8(12):3782-7. PubMed ID: 12473590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer.
    Kikuchi S; Yamada D; Fukami T; Masuda M; Sakurai-Yageta M; Williams YN; Maruyama T; Asamura H; Matsuno Y; Onizuka M; Murakami Y
    Clin Cancer Res; 2005 Apr; 11(8):2954-61. PubMed ID: 15837747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alterations of p14ARF and p16INK4a genes in salivary gland carcinomas.
    Nishimine M; Nakamura M; Kishi M; Okamoto M; Shimada K; Ishida E; Kirita T; Konishi N
    Oncol Rep; 2003; 10(3):555-60. PubMed ID: 12684623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypermethylation of p16(INK4a) and p15(INK4b) genes in non-small cell lung cancer.
    Kurakawa E; Shimamoto T; Utsumi K; Hirano T; Kato H; Ohyashiki K
    Int J Oncol; 2001 Aug; 19(2):277-81. PubMed ID: 11445839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer.
    Hsu HS; Wen CK; Tang YA; Lin RK; Li WY; Hsu WH; Wang YC
    Clin Cancer Res; 2005 Aug; 11(15):5410-6. PubMed ID: 16061855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
    Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
    Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alteration of DNA methyltransferases contributes to 5'CpG methylation and poor prognosis in lung cancer.
    Lin RK; Hsu HS; Chang JW; Chen CY; Chen JT; Wang YC
    Lung Cancer; 2007 Feb; 55(2):205-13. PubMed ID: 17140695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypermethylation of E-cadherin gene is frequent and independent of p16INK4A methylation in non-small cell lung cancer: potential prognostic implication.
    Shimamoto T; Ohyashiki JH; Hirano T; Kato H; Ohyashiki K
    Oncol Rep; 2004 Aug; 12(2):389-95. PubMed ID: 15254707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between alterations of p16(INK4a) and p14(ARF) genes of CDKN2A locus and gastric carcinogenesis.
    Tang S; Luo H; Yu J; Yang D; Shu J
    Chin Med J (Engl); 2003 Jul; 116(7):1083-7. PubMed ID: 12890389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of p27KIP1 expression in resected non-small cell lung cancers: analysis in combination with expressions of p16INK4A, pRB, and p53.
    Hirabayashi H; Ohta M; Tanaka H; Sakaguchi M; Fujii Y; Miyoshi S; Matsuda H
    J Surg Oncol; 2002 Dec; 81(4):177-84; discussion 184. PubMed ID: 12451621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allelic loss on chromosome 3p21.3 and promoter hypermethylation of semaphorin 3B in non-small cell lung cancer.
    Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Williams NN; Kaiser LR; Croce CM
    Cancer Res; 2003 Jun; 63(12):3352-5. PubMed ID: 12810670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
    Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
    Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.